Casa
avenge

Avenge Bio

Por um escritor misterioso

Descrição
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Avenge Bio
MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk
Avenge Bio
Avenge Bio to Begin Clinical trials of Immunotherapy Technology, Department of Bioengineering
Avenge Bio
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio
Avenge Bio
Avenge Bio
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio
MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk
Avenge Bio
Michael Heffernan
Avenge Bio
Aadhar Mahajan - Project Management at Avenge Bio
Avenge Bio
Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…
Avenge Bio
Rice lab's 'drug factory' implants cleared for human trials, Rice News, News and Media Relations
Avenge Bio
avengebio (@AvengeBio) / X
Avenge Bio
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio
Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma
Avenge Bio
BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial
de por adulto (o preço varia de acordo com o tamanho do grupo)